CDKN2A and neoplasm: The observation of progressive tumor growth during treatment is consistent with our more recent preclinical studies that showed no significant impact on survival rates from PLX4720 monotherapy when treating mice with distinct BRAFV600E mutant and CDKN2A deficient tumors models (intracranial xenografts from pilocytic astrocytoma [21] and glioblastoma [22]).